It cleared amyloid plaques completely from the brain in some participants, who were then taken off the drug.Īnother potential advantage for donanemab, according to Howard Fillit, chief scientist at the US-based Alzheimer’s Drug Discovery Foundation, is that patients receive infusions twice as frequently for lecanemab-every two weeks. AdvertisementĪlthough the clinical trial designs for the two drugs make direct comparisons difficult, there were tentative indications that donanemab might be more effective than lecanemab when administered to people in the earliest stages of Alzheimer’s, said Oakley. The drug slowed the progression of the disease most effectively in its earlier stages.
The donanemab trial involved 1,736 participants with an average age of 73 who had mild to moderate symptoms of Alzheimer’s, with half receiving intravenous infusions of the treatment and half a placebo every four weeks for 18 months. “The past eight months have been a real turning point, as two drugs are shown to slow down the progression of the disease after decades of work with no positive findings,” said Richard Oakley, associate director of research at UK charity the Alzheimer’s Society. Submissions are underway to other global regulators.Įxperts on dementia called Lilly’s donanemab presentation, published in the Journal of the American Medical Association, a landmark in the field. The peer-reviewed results follow similar phase 3 findings released last November by US biotech Biogen and Japan’s Eisai for lecanemab, another antibody drug, which received full marketing approval from the US Food and Drug Administration this month under the brand name Leqembi.Įli Lilly announced on Monday that it had submitted donanemab for FDA approval and expected a decision before the end of this year. The US pharmaceuticals group on Monday reported full findings of its phase 3 clinical study of donanemab at the Alzheimer’s Association International Conference in Amsterdam, showing that the antibody treatment slowed progression by about 35 percent in the early stages of the disease. Dementia experts have hailed the latest landmark in the treatment of Alzheimer’s after Eli Lilly released trial results that showed its new drug significantly slowed memory loss and cognitive decline.
0 kommentar(er)
